SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkpoint Therapeutics, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - March 11, 2025) - Rigrodsky Law, P.A. is investigating Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT) regarding possible breaches of fiduciary duties and other violations of law related to Checkpoint's agreement to be acquired by Sun Pharmaceutical Industries Limited. Under the terms of the agreement, Checkpoint shareholders will receive $4.10 per share in cash and a contingent value right for up to $0.70 per share on achievement of a milestone.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-checkpoint-therapeutics-inc.

To contact Seth D. Rigrodsky or Gina M. Serra cost free, call (302) 295-5310 or email [email protected].

Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244124

You May Also Be Interested In

• PG&E Corp, Edison spike on chatter
• ThriveCart Helps Businesses Prepare for Europe's Changing E-Invoicing Rules
• NSJ Gold Corp. (NSJ) (9PZ) Increases Flow-Through Financing for Exploration on Its Antimony 2.0 Property